Shattuck Labs, Inc. (STTK)

Shattuck Labs' stock has experienced significant movement in the past six months. As of March 26, 2026, the share price was $6.31, a 453.51% increase compared to March 27, 2025. The stock price increased by 210.85% over the last 12 months. A notable event was the company's Q4 and full-year 2025 financial results, reported on March 5, 2026, which led to a 53% share increase over five trading days. Despite this, the stock decreased by 7.60% in the month leading up to February 20, 2026.

Shattuck Labs, Inc. does not experience typical demand seasonality for its products and services. The demand for its drug candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for treatments for inflammatory, immune-mediated diseases, and cancer. Demand is not influenced by seasonal consumer patterns but rather by scientific milestones and the eventual market adoption of its therapies.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory, immune-mediated diseases, and cancer. Its major product candidates include SL-325, a DR3 blocking monoclonal antibody in Phase 1 clinical trials; SL-425, a half-life extended version of SL-325; DR3-based bispecific antibodies; TRIM7, an oncology-focused program; SL-172154, designed to block the CD47 immune checkpoint and agonize the CD40 pathway; and SL-279252, in Phase 1 clinical trial for patients with advanced solid tumors and lymphoma. The company also has a proprietary Agonist Redirected Checkpoint (ARC®) platform and a Gamma Delta T Cell Engager (GADLEN™) platform.

Shattuck Labs, Inc. is headquartered in Austin, Texas, with research and development facilities in Durham, North Carolina. The company primarily serves the U.S. market and is preparing for broader geographic reach as its clinical programs advance.

Shattuck Labs' brand reputation has been positively influenced by the advancement of its clinical programs and favorable financial reporting. The company's stock soared over 53% in early March 2026 following a well-received earnings report for Q4 and full-year 2025. There is no readily available information suggesting negative events that have significantly impacted Shattuck Labs' broader public reputation in the past year.

Shattuck Labs, Inc. has a diverse ownership structure, with institutional investors holding approximately 40.37% to 58.73% of the stock, insiders owning around 14.50% to 20.75%, and retail investors holding approximately 20.53% to 35.65%. Hedge funds own about 27% of Shattuck Labs. Major institutional owners include Adage Capital Partners Gp, L.l.c., OrbiMed Advisors LLC, Redmile Group, LLC, NEXTBio Capital Management LP, Prosight Management, LP, Vanguard Group Inc, Price T Rowe Associates Inc /md/, T. Rowe Price Investment Management, Inc., and BlackRock, Inc.